EQL Pharma out-license Mellozzan to a leading European pharmaceutical Company for two major Southern European geographies
EQL Pharma has today entered into an exclusive out-licensing agreement with a leading European pharmaceutical company for EQL's proprietary product Mellozzan (melatonin) for two major geographies in Southern Europe. The agreement is in practice without a set time limit and applies to tablets in six different strengths as well as an oral solution. Both formulations are ready to send in for registration in the two countries.Mellozzan is a medicine given to children with sleep disorders who have ADHD and where sleep hygiene measures are not enough. In the ADHD patient group insomnia is very